Increasing incidences of diabetes and cancer is leading to rise in the usage of PCA (patient-controlled analgesia) pumps. Decreasing preferences for standard continuous infusion systems, reduction in hospital costs and launch of quality indicators is contributing significantly towards global market growth. Trends such as fast med-tech progress, changing manufacturing base to developing economies and user-friendly innovative equipments will drive the market sales in the forthcoming years. However, lack of usage of standard guidelines, low skilled manpower and extensive product recalls is expected to restrain the global market growth.
A recent report evaluates that the global market for patient-controlled analgesia pumps will expand at a steady 5.2% CAGR during the forecast period, to reach an evaluation of over US$ 500Mn by 2026-end. Companies namely Moog Inc., B Braun Melsungen AG, Baxter International, Smiths Group plc, Ace Medical Co. Ltd., Terumo Corporation, Hospira (Pfizer Inc.), Micrel Medical Devices S.A., Becton, Dickinson and Company and Fresenius SE & Co. KGaA among others will observe a notable growth globally. Leading companies are working on marketing plans such as product improvements and expanding their product portfolio. Apart from this, companies such as Pacira Pharmaceuticals are contributing towards expansion of the global market.
Pacira Pharmaceuticals Announces FDA Approval of Its EXPAREL®
Pacira Pharmaceuticals recently announced that it received the U.S. FDA (Food and Drug Administration) approval for its sNDA (supplemental new drug application) to expand the usage of EXPAREL®, which is a bupivacaine liposome injectable suspension. This approval was needed for including administration through interscalene method to brachial plexus block, for producing postsurgical regional analgesia. Apart from this, EXPAREL® has now become first long-acting and the only dose nerve block, obtainable for patients suffering from upper extremity operations such as rotator cuff repair or total shoulder arthroplasty.
Brachial plexus blocks have developed as a support of postoperative pain control for the upper extremity operations and are appropriately positioned for compromising over 60% regional nerve block processes in a time span of two years. According to current analysis, over 3Mn patients were treated with the help of EXPAREL®. This technology helps the clinicians in potentially eliminating the requirement for cumbersome pumps and catheters, which are usually utilized for extending the time of regional analgesia.
Holistically, there is a serious requirement for non-opioid options in the postoperational setting that will help in reducing pain at the operation site and eliminate the necessity for opioids. The capability to deliver effective regional analgesia along with one dose of EXPAREL® is highly beneficial for patients and improves the vital requirement for opioid pain management schemes.
Insights on EXPAREL®
The protection profile for EXPAREL® in interscalene method to brachial plexus nerve block analysis was reliable with the earlier described safety profile of EXPAREL® in injury infiltration. It also includes profile of the bupivacaine when utilized as brachial plexus nerve block. The analysis randomized 156 patients within 17 sites in 1:1 ratio for receiving one dose of either EXPAREL®133 mg in ten ml, extended in volume along with 10 ml of standard saline for a volume of 20 ml. EXPAREL® is administered as one dose brachial plexus block, under ultrasound regulation, for at least an hour before the surgery. Every patient is eligible to obtain postsurgical release opioids upon demand for pain control.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5710